Harmony Biosciences is broadening beyond Wakix with pitolisant programs, orexin research and rare epilepsy assets to ...

Richard Bogan, MD, discusses trial data coming out of the VIBRANCE studies for patients with narcolepsy type 2 and idiopathic hypersomnia. A dose-finding, placebo-controlled study of an orexin agonist ...

The VIBRANCE-3 trial will evaluate the safety and efficacy of varying alixorexton doses by measuring changes in the Epworth Sleepiness Scale from baseline to week 8. The Food and Drug Administration ...

Phase 4 DUET enrolled adults with NT1/NT2 or idiopathic hypersomnia (ESS >10) and showed ≥2-point ESS reductions in 82% of narcolepsy and 95% of hypersomnia participants. Normal-range ESS (≤10) was ...

Blair Jackson says the next 12 months may be the most important in Alkermes’ history, as the brain drugmaker races to join an ...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced 11 late-breaking presentations at SLEEP 2026, including notable new research showcasing the comprehensive treatment outcomes of Xywav® (calcium, ...

Alkermes ( (ALKS)) just unveiled an update. On June 15, 2026, Alkermes announced that alixorexton, its investigational oral selective orexin 2 receptor agonist for narcolepsy type 1, narcolepsy type 2 ...

Eli Lilly's spate of acquisitions is building out multiple areas of its pipeline at once.

In June 2026, Alkermes plc reported detailed positive phase 2 Vibrance‑2 results for its oral orexin 2 receptor agonist ...

If you're tired all the time, you might not just be bad at sleeping. You could actually have a medical condition.

Avadel acquisition adds LUMRYZ sales momentum; alixorexton Phase 2/3 data supports growth. Click for this ALKS stock update.

Q: I’m always tired. I try to prioritize sleep but always end up exhausted despite my best efforts. Why don’t I ever feel ...